Navigation Links
MEDIHONEY Used to Prevent Amputation of Patient's Leg
Date:1/13/2009

Clinicians at major NY hospital tout MEDIHONEY(TM) at press conference

PRINCETON, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that MEDIHONEY was the focus of a major press conference last week at North Shore Long Island Jewish Hospital in Manhasset, NY. At the press conference, clinicians detailed the case of a patient who appeared to be heading towards a lower extremity amputation (LEA) due to a non-healing wound associated with an extremely rare fungal infection.

Video clips of the press conference were subsequently aired on several new broadcasts throughout the NY region. To view these clips, please go to the following links:

http://www.newsday.com/news/health/ny-lihone0109,0,7667575.story

http://abclocal.go.com/wabc/story?section=news/health&id=6593764

According to Mary Brennan, RN, CWOCN, Clinical Nurse Specialist for Wounds at North Shore, "MEDIHONEY helped to turn this wound around for him and allowed us back on track for healing. We had used other therapies, but this was the product that made the difference in a very short time."

There are over 50,000 LEAs each year in the United States alone. The 3-year mortality rate post-LEA is estimated to be around 50%.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey- based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from the University of Southern California in Q4 of 2007. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

    Contact: Derma Sciences, Inc.             Allen & Caron Inc
             Edward J. Quilty                 Rudy Barrio (US Investors)
             Chairman and CEO                 r.barrio@allencaron.com
             equilty@dermasciences.com
             (609) 514-4744                   Brian Kennedy (media)
                                              brian@allencaron.com
                                              (212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Derma Sciences Launches Two New MEDIHONEY(TM) Formulations
2. Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter
3. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming WUWHS Conference
4. Derma Sciences MEDIHONEY(TM) Profiled By ABC News Philadelphia Affiliate
5. Derma Sciences Receives Third FDA Clearance for MEDIHONEY(TM) Wound & Burn Dressings
6. New Study Shows the Use of MEDIHONEY(TM) Wound & Burn Dressing is Associated With Reduction in Wound Size
7. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference
8. Derma Sciences Announces Several Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming APWCA Conference
9. American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness
10. College of American Pathologists Offers Tips on Simple Diabetes Prevention in the New Year
11. Photos: Arthritis Foundation Launches Nationwide Movement Encouraging People to Move to Prevent and Treat Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of ... a new solution for Emergency Departments (ED) has been added to their portfolio. ... Department examination rooms, and with a simplified pallet of information available to the ...
(Date:12/8/2016)... ... 2016 , ... The West Virginia Medical Institute (WVMI) announced ... name change aligns the entire company with its existing Quality Insights branded projects ... are very proud of the achievements associated with the West Virginia Medical Institute ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has ... general counsel and Eric Hoessel to vice president of sales. , Litsinger ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 6.83% during the period ... growth prospects of the global travel vaccines market for 2016-2020. To ... the sales of various vaccines administered to actively immunize meningococcal disease, ...
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... newly issued shares of common stock, $0.01 par value (the ... underwritten public offering.  The final terms of the Offering will ... pricing, and there can be no assurance as to whether ... expects to use the net proceeds it will receive from ...
Breaking Medicine Technology: